96740-92-0

Usage

Uses

Used in Pharmaceutical Synthesis:
3-Fluoro-4-(hydroxymethyl)phenol is used as a reactant in the synthesis of cyanophenyl(triazolyl)aminomethylphenyl sulfamates, which are dual aromatase-sulfatase inhibitors. These inhibitors are important in the development of treatments for hormone-dependent conditions and diseases, such as breast cancer, endometriosis, and certain types of infertility.
Used in Chemical Research:
Due to its distinctive structure, 3-fluoro-4-(hydroxymethyl)phenol can also be utilized in chemical research for studying the effects of fluorination and functional group modifications on the reactivity and properties of phenolic compounds. This can lead to the discovery of new synthetic pathways and applications in various fields, including materials science and medicinal chemistry.

Upstream product

• 65145-13-3 2-fluoro-4-hydroxybenzoic acid 
• 348-27-6 2-fluoro-4-hydroxybenzaldehyde 
• 197507-22-5 methyl 2-fluoro-4-hydroxybenzoate 
• 203115-96-2 2-fluoro-4-propoxybenzoic acid 

Downstream Products

• 214554-35-5 (3-Fluoro-4-hydroxymethyl-phenoxy)-acetic acid ethyl ester 
• 1037776-15-0 3-fluoro-4-hydroxymethylphenyl propionate 
• 504414-33-9 4-benzyloxy-2-fluoro-benzyl alcohol 
• 1472068-01-1 4-[(2-fluoro-4-hydroxybenzyl)(4H-1,2,4-triazol-4-yl)amino]benzonitrile 
• 1472067-88-1 4-{[(4-cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}-3-fluorophenylsulfamate 
• 1432045-99-2 4-(benzyloxy)-1-(chloromethyl)-2-fluorobenzene 
• 1472068-49-7 4-{[4-(benzyloxy)-2-fluorobenzyl](1H-imidazol-1-yl)amino}benzonitrile 
• 1472068-50-0 4-[(2-fluoro-4-hydroxybenzyl)(1H-imidazol-1-yl)amino]benzonitrile 
• 1472067-99-4 4-{[(4-cyanophenyl)(1H-imidazol-1-yl)amino]methyl}-3-fluorophenylsulfamate 
• 1260775-96-9 C₇H₆ClFO 
• 214554-36-6 3-fluoro-4-(hydroxymethyl)phenoxyacetic acid 

Relevant academic research and scientific papers

Circumventing seizure activity in a series of G protein coupled receptor 119 (GPR119) agonists

Agonism of GPR119 is viewed as a potential therapeutic approach for the treatment of type II diabetes and other elements of metabolic syndrome. During progression of a previously disclosed candidate 1 through mice toxicity studies, we observed tonic-cloni

SUBSTITUTED PIPERIDINE DERIVATIVES AND METHODS FOR PREPARING THE SAME

The present invention relates to a novel compound or a pharmaceutically acceptable salt thereof, a preparation method thereof and a pharmaceutical composition for treating metabolism-related disorder containing the same. Specifically, the present invention relates to a compound of the formula 1, which can activate GPR119 to treat metabolism-related disorders, including diabetes and related diseases, diabetes-related microvascular complications, diabetes-related macrovascular complications, cardiovascular abnormalities, metabolic syndrome and its constituent diseases, and obesity.

Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate

4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs). Structure-activity relationship studies were performed on these

Electronically modified polymer-supported cinchona phase-transfer catalysts for asymmetric synthesis of α-alkyl-α-amino acid derivatives

Merrifield resin-supported hydrocinchonidinium salts containing particular functional groups that can participate in hydrogen bonding were prepared and evaluated as chiral phase-transfer catalysts using the asymmetric benzylation of glycine imine ester. These electronically modified Merrifield resin-supported phase-transfer catalysts generally provided better enantioselectivities compared to the unmodified ones. Copyright

Fluorinated linkers for monitoring solid-phase synthesis using gel- phase 19F NMR spectroscopy

Three fluorinated linkers which are analogues of linkers commonly used in solid-phase peptide synthesis have been prepared. Using 19F NMR spectroscopy, the fluorine atom of the linker allowed monitoring of several transformations in the solid-phase synthesis of a peptoid having a coumarin moiety. Especially, attachment of the linker to the solid phase, coupling of the first building block to the linker and cleavage of the product were efficiently monitored and optimised.